Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
US10894044B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 16, 2016 |
| Grant date | Jan 19, 2021 |
| Priority date | — |
| Expiry date | Apr 27, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to compositions and methods for treating cancer, more specifically to methods and compositions comprising a Topoisomerase I inhibitor and an α-PD-L1 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.